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Contribution and relevance to the field
In vitro studies on NF-κB signalling have contributed
much to our understanding of the multiple effects of
NF-κB. However, beyond the largely descriptive studies of
NF-κB-related phenotypes in animal models, few studies
have addressed precisely how NF-κB mediates its effects
in vivo.
The study by Cao and coworkers [1] provides insight into
a NF-κB-dependent signalling pathway with a specific
phenotypic outcome in vivo, placing NF-κB as a key regu-
lator of epithelial growth in the developing mammary
gland. In the light of previous reports demonstrating a role
for NF-κB in survival of mammary epithelial cells [2,3], the
underlying implication of the present study is that the func-
tion of NF-κB in mammary epithelial cells is context depen-
dent and relies on a level of signalling specificity
previously not appreciated.
The study involves the use of an inactivatable mutant of
IKKα, a component of the heterotetrameric IkB kinase
(IKK) complex responsible for activation of NF-κB by a
variety of stimuli, which is thought to convey development-
specific signals to NF-κB [4]. Interestingly, this mutant line
(unlike IKKα null mice) was normal in nearly all respects
(including NF-κB responses to proinflammatory stimuli)
albeit for an abnormal mammary development, similar to
that of the receptor activator of NF-κB (RANK)-deficient
mice. The morphology of the IKKαaa/aa mammary gland
was consistent with the expected timing of NF-κB activa-
tion in normal mammary glands of gestating mice [2]. This
represents an important tissue specificity in IKKα-depen-
dent signalling, which may have implications in other NF-
κB settings and in the treatment of breast cancers.
With an upstream IKKα pathway identified, Cao et al.
turned to probable downstream NF-κB targets that could
be mediating the IKKα-dependent phenotype. A previous
report of a similar mammary phenotype for cyclin D1
knockout mice [5] prompted them to look at cyclin D1
expression in their IKKα mutant mice. Confirmation of a
marked reduction in cyclin D1 expression in these mice led
to the ‘clinching’ experiment: overexpressing a cyclin D1
transgene in IKKα mutant mice rescued the IKK pheno-
type in the mammary gland. This observation confirmed
the hypothesis that NF-κB regulated the cell cycle during
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gestation, and firmly established a linear pathway from
RANK, via NF-κB, to cyclin D1.
The observation that NF-κB is responsible for proliferation
of mammary epithelial cells during pregnancy is in itself
not new. Brantley and colleagues had previously demon-
strated that NF-κB positively regulated mammary epithelial
proliferation, ductal branching and maintenance of overall
mammary structure [6]. However, Cao et al.’s study is
significant not only in its identification of the specific
signalling pathway responsible for this NF-κB action in the
mammary gland, but also in the manner in which it is
achieved. The elegant use of crosses between the IKKα
mutant and other transgenic lines, previously demon-
strated to have mammary phenotypes, combined with
tissue-restricted expression of these transgenes, thus
demonstrates the increasing power of transgenics in the
elucidation of complex signalling pathways.
Future perspectives
Two intriguing questions arise from the elucidation of this
pathway in the mammary gland. How is the specificity for
IKKα in the mammary gland achieved, and does the func-
tion of NF-κB change during the course of mammary
development? Central to these questions is the identity of
the NF-κB isoforms regulated throughout the mammary
cycle. Could changes in signalling specificity upstream of
NF-κB result in a shift in the ratio of activated NF-κB iso-
forms with subsequent changes in target gene expression
and cellular phenotype? This has not been properly
addressed for the complete mammary cycle and warrants
further investigation. p52 processing was shown to be
affected in IKKα mutant mice in the study of Cao et al. The
relatively low level of the p52 isoform compared with the
p65 and p50 isoforms, and the fact that there is no
mammary phenotype in p52-deficient mice [7,8], however,
suggest that this has little or no role prior to lactation.
The relative contributions of IKKα and IKKβ to the sig-
nalling complex vary according to the requirements of the
cell. IKKβ plays a predominant role in immune responses,
while IKKα alone appears to be sufficient for at least some
developmental systems [9–11]. Cao et al. suggest that
the relative contribution of IKKα and IKKβ to downstream
NF-κB activation may occur via alternate upstream
kinases, one of which is NIK and the other yet to be
defined. This conclusion is supported in an earlier study of
human fibroblasts [12].
Perhaps disproportionate activation of components of the
IKK complex determines NF-κB responses to specific
changes in the local environment during mammary
development. NF-κB DNA binding activity is biphasic
during mammary development, being downregulated after
pregnancy and during lactation, and reactivated at the
onset of involution [2]. RANK expression is negligible in
involution (Clarkson, unpublished observations, 2002) and
is therefore unlikely to be the predominant NF-κB stimulus
at this time. Tumour necrosis factor (TNF) and Fas recep-
tor expression is elevated during involution, and Fas-defi-
cient mice exhibit a mammary involution phenotype [13].
Given that IKKαaa/aa cells show normal IKK and NF-κB
activation in response to TNFα, it is intriguing to postulate
whether TNFα or Fas, via IKKβ rather than IKKα, may be
responsible for the activation of NF-κB in involution.
Could NF-κB thus have distinct roles in pregnancy
(proliferation) and involution (survival)? There is increasing
evidence in the mammary gland and other tissues that this
could indeed be the case. Observation of NF-κB in a
regressing mammary gland in vivo and intervention of
NF-κB in vitro suggested a role for NF-κB in mammary
epithelial apoptosis [2,3,14]. This fits with the paradigm of
NF-κB action in other cell types, particularly given the con-
comitant expression of TNF-receptor family members in
mammary epithelial cells during involution.
Since the first conclusive description of NF-κB acting as a
survival factor [15,16] downstream of TNFα, literally
hundreds of studies have reported the role of NF-κB in
apoptotic programmes in a variety of contexts. This may
have had the effect of skewing perception of the role of
NF-κB in developing tissues, including the mammary
gland. Indeed, our study of NF-κB activity in a normal
mammary gland concentrated on its role in involution [2].
Studies describing altered NF-κB activities in breast
cancers refer to apoptosis as a likely causal mechanism.
Cao  et al.’s timely contribution to the field has re-
addressed this balance, highlighting the importance of
NF-κB in cell growth during development and its possible
relevance to breast cancers.
While evocative, Cao et al.’s suggestion that their obser-
vations might explain the association between NF-κB and
breast cancer belies an inconsistency in the available
evidence. There have been several reports describing con-
stitutive activity of NF-κB isoforms in human breast cancer
cell lines and in primary tumours [17–20]. It is unclear
from these studies, however, whether NF-κB activation or
suppression contributes to carcinogenesis, which iso-
forms are aberrantly regulated or, indeed, whether NF-κB
has a causal role rather than simply being a marker of
tumour differentiation. While the study of Brantley and
coworkers [6] seemed to implicate NF-κB directly in the
phenotypic transformation of mammary epithelial cells in
virgin mice, the mechanism underlying this activity
remained undefined. Direct regulation of cyclin D1 is,
however, a promising proposition, as it is overexpressed in
50% of human primary breast cancers [21]. If NF-κB is
found to be a major contributory factor to human breast
cancers then the approach described by Cao et al., to
specifically target IKKα signalling and to thereby circum-175
vent proinflammatory pathways, would be an attractive
proposition.
An alternative role for NF-κB in the mammary gland has
been proposed by Soler and colleagues [22]. Their
studies have implicated NF-κB in the maintenance of the
epithelial barrier during remodelling of the mammary gland.
This is relevant to all stages of mammary development.
These reports, taken together, support the view that
NF-κB has different roles to play at different times during
mammary development. At this stage, however, we cannot
exclude the possibility that NF-κB is exclusively linked to
cell-cycle regulation during involution.
Conclusion
What do Cao et al.’s results mean for the future of NF-κB
research? An in vivo study of NF-κB in mammary involu-
tion is clearly required and will no doubt be forthcoming in
the near future. Use of conditional transgenics (IKKαaa/aa
and IKKβaa/aa) mutants, activated at or around the onset of
involution, would help to establish the relative contribution
of each of these signalling components in mammary
regression. Identification of the NF-κB isoforms through-
out the mammary cycle may also help to determine the
phenotypic outcome and alternative upstream pathways
responsible for apoptosis and/or proliferation, and may
shed light on previous observations in breast cancer cells.
The present study has raised the possibility that two dis-
tinct NF-κB signalling pathways exist during mammary
gland development. As one of these pathways has been
identified, it now remains to be seen whether a similar
approach reveals a second pathway later in the develop-
mental cycle.
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